Hugues Dolgos, Nerviano Medical Sciences CEO

Mer­ck KGaA teams up with Ital­ian on­col­o­gy group in PARP1 de­vel­op­ment deal

An Ital­ian group has al­lied it­self with Mer­ck KGaA in an on­col­o­gy li­cens­ing deal, seek­ing to get in on the mar­ket op­por­tu­ni­ty and ex­pand its reach in a pos­si­bly block­buster mar­ket.

Mer­ck KGaA and Ital­ian on­col­o­gy com­pa­ny Ner­viano Med­ical Sci­ences joint­ly an­nounced Wednes­day that they are col­lab­o­rat­ing on a li­cens­ing deal for NMS’s PARP1 in­hibitor. Called NMS-293, the drug can­di­date is cur­rent­ly in clin­i­cal tri­als to treat pa­tients as a monother­a­py with a spe­cif­ic type of tu­mor: BR­CA-mu­tat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.